- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Salt substitute cost-effective compared to antihypertensive drugs for treating prehypertensive individuals: Study
A recent study published in the Hypertension journal highlights the cost-effectiveness of salt substitution over antihypertensive drug treatment in managing prehypertension among Chinese adults, particularly for the individuals aged 40 and above. The findings illuminate the potential for significant public health benefits and cost savings through early lifestyle interventions.
The research incorporated data from the China Kadoorie Biobank, using real-world information on cardiovascular disease (CVD) events, costs, and quality-adjusted life years (QALYs). By utilizing Markov cohort model, this study evaluated 3 interventions: salt substitution, antihypertensive drug treatment, and a combination of both. Costs and utilities were derived from published sources, and the interventions were assessed across different age groups and risk levels. Incremental cost-effectiveness ratios (ICERs) provided a measure of value for each intervention per QALY gained.
By replacing traditional salt with a salt substitute for prehypertensive individuals starting at age 40 proved to be the most cost-effective strategy. With an ICER of $6413.62/QALY, this intervention showed substantial benefits in reducing CVD risk without the high costs associated with drug treatments.
For individuals at high risk of CVD, combining salt substitution with antihypertensive drug treatment offered the greatest reduction in CVD events. Initiating this combined approach at age 40 was effective by achieving a 5.3% reduction in CVD events with an ICER of $2913.30/QALY. This represented a better value when compared to starting at older ages, where the cost per QALY gained increased significantly.
Across all interventions, younger starting ages yielded better outcomes and lower ICERs. For instance, initiating a combined intervention at age 40 reduced CVD events by 5.3% when compared to 4.9% at age 70. Further, the cost per QALY gained at age 70 ($32,635.33/QALY) was more than 10-times higher than at age 40. This emphasizes the importance of early intervention in managing prehypertension.
The sensitivity analyses confirmed the robustness of these findings by reinforcing the outcome that salt substitution when started early, is a highly cost-effective measure. Overall, the study found that replacing standard salt with a low-sodium salt substitute is a simple yet impactful intervention for prehypertensive adults in China by offering significant health benefits at a fraction of the cost of drug treatments.
Reference:
Sun, Z., Zhang, H., Ding, Y., Yu, C., Sun, D., Pang, Y., Pei, P., Yang, L., Chen, Y., Du, H., Hu, W., Avery, D., Chen, J., Chen, Z., Li, L., & Lv, J. (2024). Cost-Effectiveness of Salt Substitution and Antihypertensive Drug Treatment in Chinese Prehypertensive Adults. In Hypertension (Vol. 81, Issue 12, pp. 2529–2539). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1161/hypertensionaha.124.23412
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751